ArticleAllergy, asthma & immunology research2022

One-Year Effectiveness and Safety of Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Korean Patients: A Real-World Retrospective Analysis.

Hanjae Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.